Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Key Points

• Wedbush has raised its price target for Dianthus Therapeutics (NASDAQ:DNTH) from $42.00 to $44.00, suggesting a potential upside of 16.22% from its previous close, and maintaining an "outperform" rating.
• Analysts from other firms, including Guggenheim and Raymond James, have also increased their price targets, indicating strong market confidence with a consensus target price of $61.00.
• Dianthus reported a loss of $0.88 per share and revenue of only $0.19 million for the latest quarter, missing expectations significantly and reflecting ongoing challenges for the company.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) had its price objective increased by investment analysts at Wedbush from $42.00 to $44.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Wedbush's price objective would indicate a potential upside of 16.22% from the company's previous close.

A number of other research analysts also recently commented on the stock. Guggenheim boosted their price objective on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday. Raymond James Financial reaffirmed an "outperform" rating and set a $63.00 price objective (up from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday. Robert W. Baird boosted their price objective on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the company an "outperform" rating in a research report on Tuesday. William Blair assumed coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an "outperform" rating on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $61.00.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $37.86 on Friday. The firm's 50 day simple moving average is $22.65 and its 200-day simple moving average is $20.43. The company has a market cap of $1.22 billion, a P/E ratio of -11.65 and a beta of 1.46. Dianthus Therapeutics has a fifty-two week low of $13.36 and a fifty-two week high of $38.59.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The firm had revenue of $0.19 million during the quarter, compared to analysts' expectations of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. On average, analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other news, CFO Ryan Savitz sold 20,000 shares of the business's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 8.15% of the company's stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Several large investors have recently bought and sold shares of DNTH. Vestal Point Capital LP raised its stake in Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. RA Capital Management L.P. raised its stake in Dianthus Therapeutics by 53.6% during the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock valued at $52,003,000 after purchasing an additional 1,000,333 shares during the last quarter. Candriam S.C.A. acquired a new position in Dianthus Therapeutics during the 1st quarter valued at $4,510,000. Octagon Capital Advisors LP raised its stake in Dianthus Therapeutics by 11.0% during the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock valued at $42,478,000 after purchasing an additional 231,500 shares during the last quarter. Finally, Alliancebernstein L.P. raised its stake in Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock valued at $21,887,000 after purchasing an additional 149,200 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.